Fig. 1 · Structure

Documents & Downloads

SRT 2183

Cat. No. A12150 CAS 1001908-89-9

Sirtuin-1 (SIRT1) activator

SRT 2183 is a selective Sirtuin-1 (SIRT1) activator with an EC1.5 value of 0.36 μM. SRT 2183 induces growth arrest and apoptosis, concomitant with deacetylation of STAT3 and NF-κB, and reduction of c-Myc protein levels.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
SIRT1 0.36 μM (EC1.5)

SRT 2183 Research Summary

This section summarizes 4 in vitro studies of SRT 2183 from 3 published references. In vitro models include sirt1 -/--derived osteoclasts; reh cells.

SRT 2183 In Vitro Studies

SRT 2183 did not affect AMPKα phosphorylation in sirt1 -/--derived osteoclasts compared with vehicle-treated osteoclasts in the RANKL co-administration design. SRT 2183 inhibited proliferation in Reh and Nalm-6 cells. In LN229 cells, SRT 2183 significantly decreased the capability to grow clonally. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

AMPKα phosphorylation in sirt1 -/--derived osteoclasts

Cell-based study · sirt1 -/--derived osteoclasts [1]

In sirt1 -/--derived osteoclasts, SRT 2183 was co-administered with RANKL at 1μM. AMPKα phosphorylation was unaffected compared with vehicle-treated osteoclasts.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
AMPKα phosphorylation (Thr172)Reported result AMPKα phosphorylation was not affected by SRT2183 administration in sirt1 -/--derived osteoclasts[1]

Literature-Reported Treatment Conditions

Treatment concentration
1μM
Exposure duration
4 days post RANKL stimulation
Method
co-administrated with RANKL
Vehicle
0.01% DMSO
Co-treatment
Other interventions in this design: M-CSF 10%; RANKL 10 ng/ml. Compound effect isolated by the comparison: SRT2183- and vehicle-treated osteoclasts.
Methods and source locations

Compound reported in the paper: SRT 2183

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > In vitro assays of osteoclast differentiation (S10); Methods > Compounds (S14, S15, S18); Results > SRT2183 inhibits osteoclastogenesis in sirt1-/--derived bone marrow macrophages (S72); Fig 4 legend (S131, S132)

AMPKα phosphorylation (Thr172): AMPKα phosphorylation (Thr172); comparator: vehicle-treated osteoclasts — Results > SRT2183 inhibits osteoclastogenesis in sirt1-/--derived bone marrow macrophages (S72); Fig 4 legend (S131)

Proliferation inhibition in Reh cells

Cell-based study · Reh cells [2]

In Reh cells, SRT 2183 treatment inhibited proliferation, with an IC50 of approximately 8.7 μℳ at 48 h.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
inhibition of proliferationIC50 approximately 8.7 μℳ[2]

Literature-Reported Treatment Conditions

Exposure duration
48 h
Vehicle
dimethyl sulfoxide (DMSO)
Reported limits
Not stated in the sentences used: dose, route, control.
Methods and source locations

Compound reported in the paper: SRT 2183

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results (S4, S6); Materials and Methods > Drugs (S69); Figure 1 legend (S122)

inhibition of proliferation: inhibition of proliferation — Results (S6)

Clonal growth in LN229 cells

Cell-based study · LN229 [3]

LN229 cells were treated with SRT 2183 at 10 μM. Treatment significantly decreased their capability to grow clonally after a 2-week treatment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
number of colonies in a clonogenic assayReported result SRT2183 decreased significantly the capability of cells to grow clonally after a 2-week treatment[3]

Literature-Reported Treatment Conditions

Treatment concentration
10 uM
Exposure duration
2-week treatment
Method
incubated with 10 μM SRT2183
Vehicle
dimethyl sulfoxide (DMSO)
Methods and source locations

Compound reported in the paper: SRT 2183

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Cells, reagents, and plasmid (S7); Methods > Clonogenic assays (S18); Results > SRT2183 suppresses glioma cell growth (S59, S62)

number of colonies in a clonogenic assay: number of colonies in a clonogenic assay; comparator: vehicle control — Results > SRT2183 suppresses glioma cell growth (S59, S62)

Proliferation inhibition in Nalm-6 cells

Cell-based study · Nalm-6 cells [2]

In Nalm-6 cells, treatment inhibited proliferation, with a reported value of approximately 3.2 μℳ at 48 h.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
inhibition of proliferationIC50 approximately 3.2 μℳ[2]

Literature-Reported Treatment Conditions

Exposure duration
48 h
Vehicle
dimethyl sulfoxide (DMSO)
Reported limits
Not stated in the sentences used: dose, route, control.
Methods and source locations

Compound reported in the paper: SRT 2183

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results (S4, S6); Materials and Methods > Drugs (S69); Figure 1 legend (S122)

inhibition of proliferation: inhibition of proliferation — Results (S6)

Specifications

Manufacturer Adooq Bioscience
Actions Activator
CAS Number 1001908-89-9
Applications Sirtuin-1 (SIRT1) activator
Formula C27H24N4O2S
Molecular Weight 468.57
SMILES
O=C(NC1=C(C2=CN3C(SC=C3CN4CC[C@@H](O)C4)=N2)C=CC=C1)C(C=C5)=CC6=C5C=CC=C6

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 86 mg/mL (183.53 mM)
Water Insoluble
Ethanol 3 mg/mL (6.4 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

SRT 2183 Research References

  1. [1] Gurt I, Artsi H, Cohen-Kfir E, et al. The Sirt1 Activators SRT2183 and SRT3025 Inhibit RANKL-Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages and Down-Regulate Sirt3 in Sirt1 Null Cells. PLoS One (2015). PMID: 26226624 DOI: 10.1371/journal.pone.0134391 Source material
  2. [2] Scuto A, Kirschbaum M, Buettner R, et al. SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-κB/STAT3 complex to its promoter in malignant lymphoid cells. Cell Death Dis (2013). PMID: 23681230 DOI: 10.1038/cddis.2013.159 Source material
  3. [3] Ye T, Wei L, Shi J, et al. Sirtuin1 activator SRT2183 suppresses glioma cell growth involving activation of endoplasmic reticulum stress pathway. BMC Cancer (2019). PMID: 31319814 DOI: 10.1186/s12885-019-5852-5 Source material

Added to your cart

View Cart Checkout
Loading...